NCT03700658View on ClinicalTrials.gov

A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

October 2, 2020

Study Completion Date

October 2, 2020

Conditions

Contraception

Interventions

DRUG

TV-46046

TV-46046 will be administered per dose and schedule specified in the arm.

DRUG

Depo-subQ 104

Depo-subQ 104 will be administered per dose and schedule specified in the arm.

DRUG

TV-46046 Placebo

TV-46046 Placebo will be administered per schedule specified in the arm.

Trial Locations (1)

Unknown

Teva Investigational Site 1, Santo Domingo

All Listed Sponsors

collaborator

FHI 360

OTHER

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT03700658 - A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046 | Biotech Hunter | Biotech Hunter